Company / SG&A Expense
Inhibikase Therapeutics, Inc. SG&A Expense History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$6.7M
FY2024
5-year range
$2.6M / $6.7M
FY2021-FY2024
Trend
+8.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $7M to $7M over the past 2 years.
Based on SEC 10-K filings.
$7M in FY2024 with a 3-year CAGR of +36.9%.
Increased from $7M to $7M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +36.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +36.9%, indicating consistent growth.
- In FY2024, sg&a expense increased 8.3% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $6.7M | +8.3% |
| FY2023 | $6.2M | -4.5% |
| FY2022 | $6.5M | +148.1% |
| FY2021 | $2.6M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026